|
|
||||||||
Glasgow Royal Infirmary, Glasgow, Scotland
Miami Valley Laboratories, Procter & Gamble Company, Cincinnati, Ohio
Correspondence: For reprints contact: Ignac Fogelman, University Departments of Medicine and Nuclear Medicine, Royal Infirmary, Glasgow, G4 OSF, Scotland.
ABSTRACT
Twenty normal volunteers had measurements of 24-hr whole-body retention (WBR) of three structurally related Tc-99m-labeled phosphonate skeletal imaging agents: (1-hydroxyethylidene) diphosphonate (HEDP), methylene diphosphonate (MDP), and hydroxymethylene diphosphonate (HMDP). The average WBR values, reflecting skeletal uptake, were 18.4, 30.3, and 36.6%, respectively. These results clearly illustrate that slight alterations in diphosphonate molecular structure have a significant effect upon specificity for osseous tissue, and thus may affect skeletal image quality and the usefulness of the WBR technique in diagnosing metabolic bone disease.
This article has been cited by other articles:
![]() |
J. G. Rajendran, J. F. Eary, W. Bensinger, L. D. Durack, C. Vernon, and A. Fritzberg High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation J. Nucl. Med., October 1, 2002; 43(10): 1383 - 1390. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |